ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

Oncogens Variations May Exaplin Susceptibility, Familial Cancer, USC Investigators Report

September 23, 1988

Copeland Named Director, UF Cancer Center

February 10, 1995

Benefit Seen In Novel Drug That Treats Gleevec Resistance

April 29, 2005

NCAB Gives Okay To Comp Center Guidelines

December 7, 1979

In Brief: Comprehensive Designation To MN Center; Bernardin Center Wins NCI Planning Grant

October 16, 1998

US Sues St. Luc Hospital For Grant Funds, Expenses Of Data Reanalysis, Investigation

June 9, 1995